• Australia’s Chemgenex was brewing today after a study showed its lead drug was able to kill cancer stem cells in mice. [Bloomberg]

• Roche has closed the deal – Genentech as a public company is no more. [WSJ Health Blog]

• Lux Bioscience’s voclosporin works in uveitis trial. [Pharmalive]

• Neurotech’s cell therapy for dry AMD successful in Phase 2 study. [BusinessWire]

• Taiwan is setting up a $1.76B Biotechnology fund to boost the economy and create jobs. [AFP]

And that’s that…even slower today…

Image from genesniffer

Related Posts